semaglutide sigma aldrich Weight Loss & Metabolic Support SEMAGLUTIDE PEPTIDE VIAL – UMBRELLA

This step disinfects the skin and reduces the chance of infection

Trial OASIS 4 (oral Wegovy) Design Phase 3 / 64 weeks Population Adults with obesity, no diabetes Key result -16.6% body weight at 25 mg daily

| Sustained weight maintenance data | Limited | Yes (STEP 5, 104 weeks) | Tesofensine produces faster weight loss on a per-month basis, while semaglutide produces greater total weight loss over a longer treatment period and has demonstrated sustained results with continued use

Binvignat, M., Sellam, J., Berenbaum, F

Proper monitoring is essential to avoid potential interactions with other medications

Both groups lost a similar amount of weight about 13% of body weight over 6 months